TY - JOUR
T1 - Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib
AU - Gardini, Andrea Casadei
AU - Scarpi, Emanuela
AU - Faloppi, Luca
AU - Scartozzi, Mario
AU - Silvestris, Nicola
AU - Santini, Daniele
AU - De Stefano, G.
AU - Marisi, Giorgia
AU - Negri, Francesca V.
AU - Foschi, Francesco Giuseppe
AU - Valgiusti, Martina
AU - Ercolani, G.
AU - Frassineti, Giovanni Luca Paolo
PY - 2016
Y1 - 2016
N2 - We evalueted a systemic immune-inflammation index (SII), neutrophil-tolymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) with the aim to explored their prognostic value in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. 56 advanced HCC patients receiving sorafenib were available for our analysis. Lymphocyte, neutrophil and platelet were measured before beginning of treatment and after one month. Patient with SII ≥ 360 showed lower median PFS (2.6 vs. 3.9 months, P < 0.026) and OS (5.6 vs. 13.9 months, P = 0.027) with respect to patients with SII < 360. NLR ≥ 3 had a lower median PFS (2.6 vs. 3.3 months, P < 0.049) but not OS (5.6 vs. 13.9 months, P = 0.062) than those with NLR < 3. After adjusting for clinical covariates SII and NLR remained an independent prognostic factor for OS. The SII and NLR represent potential prognostic indicator in patients with advanced HCC treated with sorafenib.
AB - We evalueted a systemic immune-inflammation index (SII), neutrophil-tolymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) with the aim to explored their prognostic value in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. 56 advanced HCC patients receiving sorafenib were available for our analysis. Lymphocyte, neutrophil and platelet were measured before beginning of treatment and after one month. Patient with SII ≥ 360 showed lower median PFS (2.6 vs. 3.9 months, P < 0.026) and OS (5.6 vs. 13.9 months, P = 0.027) with respect to patients with SII < 360. NLR ≥ 3 had a lower median PFS (2.6 vs. 3.3 months, P < 0.049) but not OS (5.6 vs. 13.9 months, P = 0.062) than those with NLR < 3. After adjusting for clinical covariates SII and NLR remained an independent prognostic factor for OS. The SII and NLR represent potential prognostic indicator in patients with advanced HCC treated with sorafenib.
KW - Biomarker
KW - Hepatocellular carcinoma
KW - Inflammation
KW - Neutrophil-to-lymphocyte ratio
KW - Systemic immune-inflammation index
UR - http://www.scopus.com/inward/record.url?scp=84993997499&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84993997499&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.11565
DO - 10.18632/oncotarget.11565
M3 - Article
SN - 1949-2553
VL - 7
SP - 67142
EP - 67149
JO - Oncotarget
JF - Oncotarget
IS - 41
ER -